Table III.
Univariate and multivariate analyses of the association between SCGB2A1 expression with overall survival among patients with uterine corpus endometrial cancer.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Parameters | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Age (continuous) | 1.03 (0.99–1.08) | 0.156 | ‒ | ‒ |
| BMI (continuous) | 1.03 (0.97–1.09) | 0.284 | ‒ | ‒ |
| Grade (3 vs. 1 or 2) | 1.91 (0.76–4.81) | 0.167 | ‒ | ‒ |
| Stage (III or IV vs. I or II) | 5.62 (2.29–13.79) | 0.000a | 1.27 (0.50–3.22) | 0.615 |
| Peritoneal cytology (positive vs. negative) | 4.21 (1.62–10.97) | 0.003a | 2.75 (1.27–5.97) | 0.010a |
| Pelvic lymph nodes (positive vs. negative) | 1.58 (1.26–1.98) | 0.000a | 1.82 (0.77–4.33) | 0.174 |
| Para-aortic lymph nodes (positive vs. negative) | 1.57 (0.36–6.78) | 0.546 | ‒ | ‒ |
| Histology (serous vs. endometrioid) | 2.35 (0.90–6.14) | 0.081 | ‒ | ‒ |
| Myometrial invasion (>50 vs. ≤50%) | 2.62 (1.09–6.31) | 0.032a | 1.51 (0.71–3.21) | 0.290 |
| Status (with tumor vs. tumor-free) | 6.00 (2.49–14.43) | 0.000a | 3.93 (1.97–7.87) | <0.01a |
| Residual tumor (R1 or R2 vs. R0) | 3.19 (1.16–8.77) | 0.025a | ‒ | ‒ |
| SCGB2A1 expression (continuous) | 0.82 (0.72–0.93) | 0.003a | 0.88 (0.79–0.98) | 0.025a |
a
P<0.05. SCGB2A1, secretoglobin family 2A member 1; HR, hazard ratio.